WO2009105023A1 - Formulation pharmaceutique comprenant des oxabispidines/236 - Google Patents

Formulation pharmaceutique comprenant des oxabispidines/236 Download PDF

Info

Publication number
WO2009105023A1
WO2009105023A1 PCT/SE2009/050184 SE2009050184W WO2009105023A1 WO 2009105023 A1 WO2009105023 A1 WO 2009105023A1 SE 2009050184 W SE2009050184 W SE 2009050184W WO 2009105023 A1 WO2009105023 A1 WO 2009105023A1
Authority
WO
WIPO (PCT)
Prior art keywords
pellets
pharmaceutical formulation
modified release
extended release
formulation according
Prior art date
Application number
PCT/SE2009/050184
Other languages
English (en)
Inventor
Anders R Berggren
Hans Carlsson
Hans JÖNSSON
Kristina Roos
Erik SÖDERLIND
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of WO2009105023A1 publication Critical patent/WO2009105023A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention porte sur des formulations à libération modifiée comprenant des oxabispidines, telles que le composé tert-butyl(2-{7-[2-(4-cyano-2-fluorophénoxy)éthyl]-9-oxa-3,7-diazabicyclo-[3.3.1]non-3-yl}éthyl)carbamate. Lesdites formulations sont, de préférence, sous la forme de systèmes à multiples unités fournissant une libération immédiate de médicament en combinaison avec une libération prolongée de médicament durant une période de temps allant jusqu'à 24 heures. Les compositions sont utiles dans le traitement d'arythmies cardiaques et de plus fournissent la possibilité d'une détection précoce de patients répondant à une prolongation QT défavorable.
PCT/SE2009/050184 2008-02-22 2009-02-19 Formulation pharmaceutique comprenant des oxabispidines/236 WO2009105023A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3064308P 2008-02-22 2008-02-22
US61/030,643 2008-02-22

Publications (1)

Publication Number Publication Date
WO2009105023A1 true WO2009105023A1 (fr) 2009-08-27

Family

ID=40985767

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2009/050184 WO2009105023A1 (fr) 2008-02-22 2009-02-19 Formulation pharmaceutique comprenant des oxabispidines/236

Country Status (5)

Country Link
AR (1) AR070617A1 (fr)
PE (1) PE20091464A1 (fr)
TW (1) TW200940110A (fr)
UY (1) UY31669A1 (fr)
WO (1) WO2009105023A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104586809A (zh) * 2015-01-08 2015-05-06 浙江亚太药业股份有限公司 一种埃索美拉唑镁微丸肠溶片及制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344215B1 (en) * 2000-10-27 2002-02-05 Eurand America, Inc. Methylphenidate modified release formulations
WO2002013794A1 (fr) * 2000-08-14 2002-02-21 Peirce Management, Llc Formes galeniques pharmaceutiques orales pour administration pulsatile d'un agent antiarythmique
WO2002083687A1 (fr) * 2001-04-12 2002-10-24 Astrazeneca Ab Preparations 3,7-diazybicyclo [3.3.1] utilisees comme composes anti-arythmiques
US20040126427A1 (en) * 2002-12-31 2004-07-01 Venkatesh Gopi M. Extended release dosage forms of propranolol hydrochloride
WO2006135316A1 (fr) * 2005-06-13 2006-12-21 Astrazeneca Ab Nouveaux composes d'oxabispidine pour le traitement des arythmies cardiaques
WO2007083323A2 (fr) * 2006-01-23 2007-07-26 Panacea Biotec Limited. Administration orale de desmopressine et de ses sels
WO2007122635A2 (fr) * 2006-04-26 2007-11-01 Astron Research Limited Formulation à libération à libération contrôlée comprenant des médicaments anti-épilepiques

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002013794A1 (fr) * 2000-08-14 2002-02-21 Peirce Management, Llc Formes galeniques pharmaceutiques orales pour administration pulsatile d'un agent antiarythmique
US6344215B1 (en) * 2000-10-27 2002-02-05 Eurand America, Inc. Methylphenidate modified release formulations
WO2002083687A1 (fr) * 2001-04-12 2002-10-24 Astrazeneca Ab Preparations 3,7-diazybicyclo [3.3.1] utilisees comme composes anti-arythmiques
US20040126427A1 (en) * 2002-12-31 2004-07-01 Venkatesh Gopi M. Extended release dosage forms of propranolol hydrochloride
WO2006135316A1 (fr) * 2005-06-13 2006-12-21 Astrazeneca Ab Nouveaux composes d'oxabispidine pour le traitement des arythmies cardiaques
WO2007083323A2 (fr) * 2006-01-23 2007-07-26 Panacea Biotec Limited. Administration orale de desmopressine et de ses sels
WO2007122635A2 (fr) * 2006-04-26 2007-11-01 Astron Research Limited Formulation à libération à libération contrôlée comprenant des médicaments anti-épilepiques

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104586809A (zh) * 2015-01-08 2015-05-06 浙江亚太药业股份有限公司 一种埃索美拉唑镁微丸肠溶片及制备方法

Also Published As

Publication number Publication date
TW200940110A (en) 2009-10-01
AR070617A1 (es) 2010-04-21
PE20091464A1 (es) 2009-10-24
UY31669A1 (es) 2009-09-30

Similar Documents

Publication Publication Date Title
US7029701B2 (en) Composition for the treatment and prevention of ischemic events
US20210244714A1 (en) Pharmaceutical formulations containing rifaximin, processes for their obtainment and method of treating intestinal disease
US7838027B2 (en) Pantoprazole multiparticulate formulations
JPH11508578A (ja) 徐放性可逆性プロトンポンプ抑制剤を有する経口医薬品
IE61166B1 (en) Pharmaceutical formulations of acrivastine
JP6148252B2 (ja) 新規配合剤
AU2005304758A1 (en) Formulations of [1,4]diazepino[6,7,1-iJ]quinoline derivatives
US20020156133A1 (en) Oral administration forms for administering a fixed tramadol and diclofenac combination
JP2006512324A (ja) 睡眠障害の治療のための短時間作用性催眠薬を含む放出修飾組成物
WO2012001705A2 (fr) Compositions pharmaceutiques de (r)-lansoprazole
US20090220593A1 (en) Extended release dosage forms of quetiapine
US10953022B2 (en) Modified release doxycycline composition
MXPA06011322A (es) Formas de dosificacion farmaceutica que tienen propiedades de liberacion inmediata y/o liberacion controlada que contienen un agonista del receptor gabab.
ZA200608190B (en) Controleld release dosage for GABA receptor antagonist
WO2009105023A1 (fr) Formulation pharmaceutique comprenant des oxabispidines/236
CA2615137A1 (fr) Dispositif therapeutique monocouche a liberation controlee
US8173164B2 (en) Oral administration forms for administering a fixed tramadol and diclofenac combination
US20120082718A1 (en) Morphine Formulations
WO2009085310A1 (fr) Compositions pharmaceutiques à libération prolongée contenant du zolpidem

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09712230

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09712230

Country of ref document: EP

Kind code of ref document: A1